

MISSISSAUGA, Ontario--(BUSINESS WIRE)--June 15, 2021--MedX Health Corp. (“MedX” or the “Company”) (TSX-V:MDX) announces that, further to Acceptance from the TSX Venture Exchange, it has issued 360,000 common shares at a deemed issue price of \$0.20 per share, representing a total consideration of \$72,000, as compensation for consulting services rendered. The shares were issued pursuant to the prospectus exemption contained in NI 45-106 s. 2.24; subject to the criteria contained in NI 45-102 s. 2.6(3) being met, the shares are not subject to any restrictive hold period.

## **About MedX**

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in SIAMETRICS®, a well-regarded research system used to assess treatment effectiveness of a variety of skin conditions, including burns. The Company’s SIAscope® and other devices are manufactured in its ISO 13485 certified facility. The SIAscope® is a hand-held device that uses patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with the Company’s software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Turkey and Brazil. DermSecure® meets all privacy, security and relevant regulatory requirements in Canada, the US, Brazil, and the EU. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. [www.medxhealth.com](http://www.medxhealth.com)

## **Forward-looking Statements**

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.*

## **Contacts**

### **MedX Health Corp.**

Rob von der Porten, Chairman and Acting CEO

Bill Mitoulas, Investor Relations

+1.416.479.9547

[bill@medxhealth.com](mailto:bill@medxhealth.com)